logo
  

Sensient Technologies Q1 Net Income Declines; Raises Full Year Guidance

Sensient Technologies Corporation (SXT) reported that its first quarter net income declined to $30.9 million or $0.73 per share from $33.6 million or $0.80 per share, last year. Adjusted earnings per share was $0.79 compared to $0.80. Local currency adjusted EPS decreased 1.3% primarily as a result of higher interest expense and a higher tax rate.

Revenue was $384.67 million, up 4.2% from a year ago. On a local currency basis, revenue increased 3.8%.

Sensient continues to expect 2024 earnings per share to be between $2.80 and $2.90, which includes approximately 15 cents of Portfolio Optimization Plan costs in 2024. . The company continues to expect 2024 adjusted earnings per share to grow at a low to mid-single-digit rate on a local currency basis.

The company now expects 2024 revenue and adjusted EBITDA to each grow at a mid-single-digit rate on a local currency basis. The previous guidance called for 2024 revenue and 2024 adjusted EBITDA to grow at a low to mid-single-digit rate on a local currency basis.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT